Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 56.00K | 3.15M | 500.00K | 3.04M | 54.00K |
Gross Profit | -138.00K | -29.00K | 355.00K | 2.89M | -1.23M |
EBITDA | -10.49M | 5.92M | -2.60M | -7.35M | -8.74M |
Net Income | -11.14M | 5.27M | -2.68M | -8.68M | -10.87M |
Balance Sheet | |||||
Total Assets | 6.72M | 11.96M | 858.04K | 1.84M | 3.92M |
Cash, Cash Equivalents and Short-Term Investments | 3.67M | 345.00K | 532.23K | 1.31M | 527.00K |
Total Debt | 268.00K | 4.37M | 1.81M | 398.17K | 6.30M |
Total Liabilities | 6.22M | 6.61M | 38.64M | 36.95M | 9.32M |
Stockholders Equity | 641.00K | 5.47M | -37.78M | -35.11M | -5.12M |
Cash Flow | |||||
Free Cash Flow | -17.16M | -2.98M | -2.09M | -2.36M | -7.84M |
Operating Cash Flow | -17.14M | -2.48M | -2.08M | -2.25M | -7.82M |
Investing Cash Flow | -22.00K | -504.00K | 980.94K | 823.32K | -20.00K |
Financing Cash Flow | 13.21M | 10.07M | 1.31M | 1.08M | 5.96M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ¥347.74B | 11.06 | -2.99% | 3.68% | 11.77% | -10.16% | |
54 Neutral | $75.50M | ― | -1546.58% | ― | -19.45% | 31.22% | |
51 Neutral | $53.65M | ― | -59.49% | ― | 21.15% | 46.44% | |
50 Neutral | $52.57M | ― | -119.22% | ― | ― | 25.51% | |
47 Neutral | $53.43M | ― | 45.59% | ― | 34.04% | 55.34% | |
46 Neutral | $54.80M | ― | -290.21% | ― | -100.00% | 44.28% | |
39 Underperform | $64.19M | ― | -679.15% | ― | -56.88% | -57.57% |
Serina Therapeutics announced that its 2025 annual meeting of stockholders will be held on November 7, 2025. The change in the meeting date from the previous year affects the deadline for stockholder proposals, which is set for August 15, 2025. This adjustment provides stakeholders with a new timeline for submitting proposals and nominations, ensuring compliance with regulatory requirements and the company’s bylaws.
The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
On May 22, 2025, Serina Therapeutics announced the appointment of Dr. Stephen Brannan to its Board of Directors, bringing extensive expertise in neuroscience and neuropsychiatry drug development. Dr. Brannan’s experience, notably his role in the successful development of KarXT at Karuna Therapeutics, aligns with Serina’s focus on long-acting CNS treatments. Concurrently, Remy Gross departed from the Board, transitioning to a consulting role, having contributed significantly to Serina’s growth.
The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.